When it comes to brain tumor awareness, I do not think that anyone can argue with the fact that there are many therapies to take into consideration. You want to make sure that these growths are targeted, which is something that cannot be done unless the best procedures are set in place. What can be said about the ICT-107 vaccine, you may wonder? Judging from a recent report, it seems as though this one may be able to prove especially strong when it comes to survival rates amongst patients.
An article on Medical News Today went into detail about this particular matter and I do not think that it is hard to see why. Keep in mind that glioblastoma multiforme is the condition being targeted here, which is something that can be said about most other procedures related to brain tumor awareness. The level of aggression seen in this particular condition is something that no other tumor type can match. As a result, organizations along the lines of Voices against Brain Cancer are going to focus on it.
From what I have seen, this condition is one in which the cancerous cells seem to regenerate rather quickly. The cells are ones which feed off of the blood stream in the body, which means that there is a source of nourishment set in place. The American Brain Tumor Association went into detail about this as well as the level of risk that was seen. Even though this condition can come about in anyone, it seems as though said risk increases with men more than women, according to the ABTA.
The Cedars-Sinai Medical Group put together a study that would be able to bring the ICT-107 vaccine into use in a big way. The way that this drug would be put to use is that it would tell the immune system about the cancerous cells, which would then lead to a response that could kill the tumor. However, this is not a vaccine that can be administered immediately, as basic surgery is required beforehand. Once this is done, the drug is brought into the body three times a week during two-week intervals.
The results were positive, as it seems as though seven of the original sixteen patients were able to see extend survival rates. This would range between 60.7 and 82.7 months, which is quite extensive when considering survival rates for patients. In fact, six of the people involved in the study were said to be "progression-free." This means that not only did these patients have to worry about tumors coming back but they did not have to follow up with further treatment later on, which speaks volumes about the procedure in question.
An article on Medical News Today went into detail about this particular matter and I do not think that it is hard to see why. Keep in mind that glioblastoma multiforme is the condition being targeted here, which is something that can be said about most other procedures related to brain tumor awareness. The level of aggression seen in this particular condition is something that no other tumor type can match. As a result, organizations along the lines of Voices against Brain Cancer are going to focus on it.
From what I have seen, this condition is one in which the cancerous cells seem to regenerate rather quickly. The cells are ones which feed off of the blood stream in the body, which means that there is a source of nourishment set in place. The American Brain Tumor Association went into detail about this as well as the level of risk that was seen. Even though this condition can come about in anyone, it seems as though said risk increases with men more than women, according to the ABTA.
The Cedars-Sinai Medical Group put together a study that would be able to bring the ICT-107 vaccine into use in a big way. The way that this drug would be put to use is that it would tell the immune system about the cancerous cells, which would then lead to a response that could kill the tumor. However, this is not a vaccine that can be administered immediately, as basic surgery is required beforehand. Once this is done, the drug is brought into the body three times a week during two-week intervals.
The results were positive, as it seems as though seven of the original sixteen patients were able to see extend survival rates. This would range between 60.7 and 82.7 months, which is quite extensive when considering survival rates for patients. In fact, six of the people involved in the study were said to be "progression-free." This means that not only did these patients have to worry about tumors coming back but they did not have to follow up with further treatment later on, which speaks volumes about the procedure in question.
About the Author:
Visit Voices Against Brain Cancer if you're searching for some more information about brain tumor research and awareness.
0 comments:
Post a Comment